Filter News
Area of Research
- (-) Neutron Science (6)
- Advanced Manufacturing (1)
- Biology and Environment (8)
- Clean Energy (25)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (2)
- Isotopes (2)
- Materials (18)
- Materials for Computing (1)
- National Security (6)
- Quantum information Science (1)
- Supercomputing (10)
News Topics
- (-) Biomedical (2)
- (-) Cybersecurity (1)
- (-) Energy Storage (2)
- (-) Space Exploration (1)
- Artificial Intelligence (1)
- Biology (3)
- Computer Science (2)
- Coronavirus (1)
- Decarbonization (1)
- Environment (2)
- Frontier (1)
- Fusion (1)
- Materials (4)
- Materials Science (5)
- Nanotechnology (1)
- Neutron Science (18)
- Physics (3)
- Quantum Science (2)
- Security (1)
Media Contacts
Researchers at ORNL have developed a new method for producing a key component of lithium-ion batteries. The result is a more affordable battery from a faster, less wasteful process that uses less toxic material.
Researchers at ORNL and the University of Tennessee, Knoxville, discovered a key material needed for fast-charging lithium-ion batteries. The commercially relevant approach opens a potential pathway to improve charging speeds for electric vehicles.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
Scientists have found new, unexpected behaviors when SARS-CoV-2 – the virus that causes COVID-19 – encounters drugs known as inhibitors, which bind to certain components of the virus and block its ability to reproduce.
OAK RIDGE, Tenn., March 20, 2019—Direct observations of the structure and catalytic mechanism of a prototypical kinase enzyme—protein kinase A or PKA—will provide researchers and drug developers with significantly enhanced abilities to understand and treat fatal diseases and neurological disorders such as cancer, diabetes, and cystic fibrosis.